What is Foundayo?
Foundayo (generic name: orforglipron) is a once-daily oral pill manufactured by Eli Lilly. It belongs to the same drug class as Wegovy, Ozempic, and Zepbound — GLP-1 receptor agonists — but unlike those injectables, it is a small-molecule pill you can swallow without restrictions on food, water, or timing.
That convenience matters. The other oral GLP-1 on the market — Rybelsus (oral semaglutide) — requires an empty stomach, 4 ounces of plain water, and 30 minutes without food, drink, or other medications. Foundayo has none of those rules. For patients who've been deterred by weekly injections, this is the breakthrough.
FDA approval came April 1, 2026 — 294 days ahead of the scheduled PDUFA date — under the expedited review program. The agency cited the ATTAIN-1 phase 3 trial as primary evidence of efficacy and safety.
How orforglipron works
Foundayo mimics the action of glucagon-like peptide-1 (GLP-1), a hormone your gut releases after eating. It does three things:
- Slows gastric emptying. Food sits in your stomach longer, so you feel full from smaller portions.
- Acts on the brain's satiety centers. Hypothalamic GLP-1 receptors dampen hunger and reward signaling around food — what patients describe as "food noise" turning down.
- Improves blood glucose control. Stimulates insulin release when glucose is high; suppresses glucagon. This is why GLP-1s were originally developed for type 2 diabetes.
What makes orforglipron unique mechanically: it's a small molecule, not a peptide. Injectable GLP-1s (Ozempic, Wegovy, Mounjaro) are peptide drugs that would be destroyed in the stomach if swallowed — that's why they require subcutaneous injection. Orforglipron's small-molecule structure survives digestion intact.
Mechanism of action
ATTAIN-1 trial results
FDA approval rests on the ATTAIN-1 phase 3 trial, a 72-week randomized double-blind placebo-controlled study of 3,127 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity).
| Arm | Mean weight change | ≥5% loss | ≥15% loss |
|---|---|---|---|
| Orforglipron 36mg (highest) | −11.2% | 76% | 33% |
| Orforglipron 24mg | −9.4% | 68% | 22% |
| Orforglipron 12mg | −6.1% | 48% | 9% |
| Placebo | −2.1% | 13% | 2% |
Secondary endpoints showed improvements in waist circumference (−9.7 cm), systolic blood pressure (−5.6 mmHg), and HbA1c (−0.7 percentage points in the subgroup with type 2 diabetes). The trial was supported by the New England Journal of Medicine publication accompanying the approval.
Weight-loss trajectory · ATTAIN-1 (highest dose)
Mean change in body weight over the 72-week trial.
Dosing schedule
Foundayo follows a 12-week dose-escalation protocol designed to minimize gastrointestinal side effects. Each step lasts 4 weeks before increase.
| Weeks | Daily dose | Notes |
|---|---|---|
| 1–4 | 3 mg | Initiation |
| 5–8 | 6 mg | First escalation |
| 9–12 | 12 mg | Minimum effective dose |
| 13–16 | 24 mg | Step up if tolerated + weight goal not met |
| 17+ | 36 mg (max) | Maintenance at highest dose |
Take Foundayo once daily, any time of day, with or without food. Swallow whole; do not split or crush. Missed a dose? Take it as soon as you remember unless it's within 12 hours of your next dose — skip and resume normal schedule.
Side effects
The side-effect profile is similar to injectable GLP-1s — predominantly gastrointestinal, dose-dependent, and largely transient. ATTAIN-1 discontinuation rate due to adverse events: 11.6% (vs. 4.2% placebo).
| Side effect | Incidence | Notes |
|---|---|---|
| Nausea | ~24% | Most common; mild-to-moderate, peaks weeks 1-2 of each dose step |
| Diarrhea | ~16% | Usually transient |
| Constipation | ~14% | Manage with fluids + soluble fiber |
| Vomiting | ~11% | Take with caution; eat slowly + smaller portions |
| Decreased appetite | ~10% | Expected effect, not a side effect per se |
| Abdominal pain | ~7% | Severe pain radiating to back: rule out pancreatitis |
Boxed warning: like other GLP-1s, Foundayo carries a boxed warning for risk of thyroid C-cell tumors (observed in rodent studies). Not for patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Cost & insurance coverage
Foundayo's list price at launch is approximately $695/month. As with all branded GLP-1s, the cash price varies dramatically by access path:
- LillyDirect cash-pay: $349-499/month for self-pay patients ordering direct from Eli Lilly's online pharmacy.
- Commercial insurance: $25-100/month copay if approved, typically requires BMI ≥30 (or ≥27 + comorbidity) and prior authorization.
- Medicare GLP-1 Bridge: $50/month copay effective July 1, 2026 for eligible Medicare beneficiaries.
- Medicaid: coverage varies by state; 13 states explicitly cover GLP-1s for obesity as of mid-2026.
Monthly cost in the US
What Foundayo costs by payment path
Real out-of-pocket varies. Cash list price is what the pharmacy bills without insurance. Commercial copay assumes a tier-3 specialty plan. Savings-card numbers come from manufacturer programs.
$695/mo
What you pay at the pharmacy with no insurance, no coupons.
$50–$250/mo
Typical tier-3 specialty copay if your plan covers GLP-1s for your indication. Coverage is uneven.
$25–$25/mo
Commercially insured with coverage — $25/mo, max $200/fill. Not for Medicare/Medicaid. Medicare GLP-1 Bridge from Jul 1, 2026: $50/mo copay.
Prices verified against manufacturer pages and FDB pharmacy data. Last reviewed: 2026. Affordability programs change; verify eligibility directly with the manufacturer before assuming you qualify.
Where to buy
Foundayo (orforglipron) across providers
Prices verified May 2026 · Sponsored links — disclosed below
LillyDirect (90-day fill)
Best priceBest for: self-pay patients, lowest cost
Visit LillyDirect$349/mo
90-day cash-pay tier
Ro
Best for: insurance navigation
Start with Ro$399/mo
Includes consult + PA handling
MEDvi
Best for: transitioning from compounded
Start with MEDvi$449/mo
Brand-name + coaching
Push Health
Best for: PCP-coordinated care
Start with Push$695/mo
List price via partner pharmacy
Editorially independent. Provider rankings unaffected by commission.
Affiliate disclosure
What patients reported on Foundayo
Patient-reported outcomes from the ATTAIN-1 PRO substudy substudy, plus the Drugs.com community satisfaction rating. These are aggregate signals, not individual testimonials.
Lost ≥10% weight
52%
Share of participants on highest dose reaching the ≥10% threshold
Lost ≥15% weight
24%
Share of highest-dose arm reaching the ≥15% threshold
No food/water restriction
✓
Unlike Rybelsus, take any time with or without food
Trial discontinuation
13%
Adverse-event withdrawal; comparable to injectable GLP-1s
Drugs.com community rating from 38 verified user reviews. View on Drugs.com →
Source: ATTAIN-1 PRO substudy (Lilly investor briefing Oct 2025) + Drugs.com community rating accessed 2026.
How Foundayo compares
| Drug | Form | Mean weight loss | List price/mo |
|---|---|---|---|
| Foundayo | Daily pill | −11.2% | ~$695 |
| Oral Wegovy | Daily pill (fasting required) | ~−15% | ~$1,000 |
| Wegovy (injection) | Weekly injection | −14.9% | ~$1,350 |
| Zepbound | Weekly injection | −22.5% | ~$1,060 |
Trade-offs are real: Foundayo loses the dose battle to injectables but wins on convenience, no needles, and (likely) better long-term adherence. For patients who'd otherwise not take an injectable, pill-form weight loss > no weight loss.
Who should consider Foundayo
Foundayo is FDA-approved for adults with:
- BMI ≥ 30 (obesity), or
- BMI ≥ 27 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, sleep apnea, cardiovascular disease).
Particularly good fit for:
- Patients who've declined injectables due to needle aversion
- Frequent travelers (no refrigeration logistics)
- Patients already on Rybelsus who want fewer dosing restrictions
- Self-pay patients seeking lower entry cost than injectable Wegovy/Zepbound
How to get a Foundayo prescription
Three main pathways:
- Telehealth providers. Ro, Hims, Sequence, MEDVi, and Push Health have added or are adding Foundayo as it becomes available. Online intake → physician review → ship to home pharmacy. Compare providers.
- LillyDirect. Eli Lilly's direct-to-patient pharmacy at cash-pay rates. Best for self-pay patients without insurance.
- Your primary care or endocrinology clinic. In-person eligibility evaluation + prior auth submitted on your behalf.
Frequently asked questions
- Is Foundayo a pill or an injection?
- Foundayo is the first FDA-approved oral (pill) GLP-1 receptor agonist for chronic weight management. Unlike oral Rybelsus (semaglutide), it has no fasting or water restrictions — take it any time, with or without food.
- How much weight can I lose on Foundayo?
- In the ATTAIN-1 trial, participants on the highest dose lost on average 11.2% of body weight at 72 weeks vs. 2.1% on placebo. Real-world results vary based on adherence, lifestyle, and starting BMI.
- Is Foundayo as effective as Wegovy or Mounjaro?
- Roughly between them: Foundayo (oral, GLP-1 only) reaches ~11% weight loss; Wegovy (injectable semaglutide) reaches ~15%; Zepbound/Mounjaro (injectable GLP-1/GIP dual agonist) reaches ~22%. Trade-off: pill convenience vs. higher absolute loss.
- How much does Foundayo cost without insurance?
- List price is approximately $695/month. Eli Lilly's LillyDirect cash-pay program may offer $349-499/month for self-pay patients. Medicare GLP-1 Bridge (effective July 1, 2026) covers Foundayo at $50/month copay for eligible enrollees.
- Will my insurance cover Foundayo?
- Coverage is rolling out throughout 2026. Most commercial plans require BMI ≥30 or BMI ≥27 with a comorbidity (hypertension, sleep apnea, dyslipidemia) and prior authorization. Medicare Bridge covers it from July 1.
- When was Foundayo FDA approved?
- April 1, 2026 — 294 days ahead of its scheduled PDUFA date under FDA's expedited review program. The approval cites the ATTAIN-1 phase 3 trial as primary evidence.
Disclosure: Health Portal is affiliate-funded but editorially independent. Provider links may be sponsored; this does not affect our editorial rankings or the clinical accuracy of this page. Clinical content reviewed by Jane Novak, MD, MPH.
